Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or Open Targets Genetics which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.
27 February 2024
Mechanisms driving diseases such as cancer, autoimmunity, Alzheimer’s and Parkinson’s could be uncovered using a new integrated single-cell approach to cellular genetic screening.
At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.
Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases
We are committed to rapid publication and making data, methods and results publicly available as soon as possible
We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data